Biblio

Author Title [ Type

] Year

Filters: Author is Cario, Gunnar [Clear All Filters]

Journal Article

Philippen L, Schub N, Günther A, Cario G, Schrappe M, Repp R, Gramatzki M. Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease. Bone Marrow Transplant. 2023.

Bader P, Rossig C, Hutter M, Ayuk FAyuketang, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, et al. CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.

Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Brüggemann M, Mejstrikova E, Cazzaniga G, Hrusak O, Szczepanowski M, et al. CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment. Blood. 2024.

Müller K, Vogiatzi F, Winterberg D, Rosner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MPauline, Brüggemann M, Cario G, et al. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Blood. 2022.

Hunger SP, Tran THoa, Saha V, Devidas M, Valsecchi MGrazia, Gastier-Foster JM, Cazzaniga G, Reshmi SC, Borowitz MJ, Moorman AV, et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023;10(7):e510-e520.

Conter V, Valsecchi MGrazia, Cario G, Zimmermann M, Attarbaschi A, Stary J, Niggli F, Pozza LDalla, Elitzur S, Silvestri D, et al. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. J Clin Oncol. 2023:JCO2301388.

Fischer U, Förster M, Rinaldi A, Risch T, Sungalee S, Warnatz H-J, Bornhauser B, Gombert M, Kratsch C, Stütz AM, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015.

Moser O, Ngoya M, Galimard J-E, Dalissier A, Dalle JHugues, Kalwak K, Wössmann W, Burkhardt B, Bierings M, González-Vicent M, et al. Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study. Bone Marrow Transplant. 2024.

Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, Hagedorn N, Chen-Santel C, Bader P, Borkhardt A, Cario G, Escherich G, Panzer-Grümayer R, et al. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. J Clin Oncol. 2019:JCO1901694.

Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, de Moerloose B, Schmiegelow K, Burns MA, et al. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. J Clin Oncol. 2023:JCO2300088.

Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H-G, Arseniev L, Beier R, Beutel G, Cario G, et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. J Clin Invest. 2023.

Sahoo SS, Pastor VB, Goodings C, Voss RK, Kozyra EJ, Szvetnik A, Noellke P, Dworzak M, Stary J, Locatelli F, et al. Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. 2021.